Maximilian Kueckelhaus, MD, MBA: No financial relationships to disclose
The skin of patients with generalized junctional epidermolysis bullosa is characterized by recurrent blistering and chronic infected wounds, which markedly impair quality of life. Approximately 40% of persons with severe junctional epidermolysis bullosa die before they reach adolescence. This session will investigate that latest research and developments in EB treatment that may pave the way for a combined cell-and-gene-therapy platform that could be used to tackle other devastating forms of epidermolysis bullosa.
